Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Artigo | IMSEAR | ID: sea-200282

RESUMO

Background: Psoriasis is a common, chronic and recurrent inflammatory disease of the skin. Methotrexate has been used in patient with psoriasis, a folic acid antagonist interfering with purine pathway and the mechanism of action in psoriasis is immune modulation and anti-inflammation. So, this study aims at monitoring the efficacy and adverse effects of methotrexate in south Indian patients with psoriasis attending a tertiary care hospital.Methods: It is a prospective, observational study conducted for a period of one year in subjects of either sex having psoriasis. Methotrexate was initiated in a single weekly oral dose of 5mg to 25mg. The efficacy was evaluated using psoriasis Area and Severity Index (PASI) score in all patients before starting methotrexate therapy and the end of first month, third month and sixth month of therapy. Adverse reaction was monitored.Results: All 40 psoriasis patients after treatment with methotrexate therapy showed improved skin lesions by falling PASI scoring at the end of first, third and sixth month of treatment. None of the patients in our study had pulmonary toxicity, life threatening adverse effects which required hospitalization.Conclusions: Use of methotrexate in the treatment of psoriasis in this study was found to be safe and highly efficacious and caused minimal adverse effects and it was well tolerated.

2.
China Pharmacy ; (12): 1187-1191, 2019.
Artigo em Chinês | WPRIM | ID: wpr-816961

RESUMO

OBJECTIVE: To establish psoriasis animal model with a longer duration and more typical psoriatic characteristics by modifying psoriasis model induced by imiquimod. METHODS: Mice were randomly divided into normal group (treated with vaseline), model group [treated with Imiquimod cream 60 mg/(2×3 cm2·d)] and modified group [treated with Imiquimod cream 60 mg/(2×3 cm2·d)+subcutaneous injection of rmIL-12 and LPS once a week], for consecutive 21 d, with 10 mice in each group. The skin of the model site was observed daily from the first day of modeling. Psoriasis area and severity index (PASI) score was conducted for skin lesions such as erythema, scales and thickening. 21 d after modeling, mice were sacrificed, and histopathological examination of the skin lesions was performed. The spleen index was calculated, and the contents of IL-17A and IL-12 in the skin were detected by ELISA. RESULTS: From the third and second day of medication, erythema, scales and thickening were both observed in model group and modified group respectively. The PASI score reached peak on the 12th day. From the 11th day, erythema, scales and thickening of the modified group were more serious than that in model group. PASI scores of modified group was significantly higher than that of model group for 9 consecutive days (P<0.05). Histopathological observation showed that Munro microabscess, acanthosis and dermal inflammatory cell infiltration occurred in both model group and modified group. Compared with model group, spleen indexes of modified group were higher (P<0.05). Compared with normal group, the contents of IL-17A and IL-12 in mice skin of model group and modified group were both increased, and there was statistical significance in modified group (P<0.05). CONCLUSIONS: The estbalished modified model has the longer duration of typical characteristics of psoriasis.

3.
Chongqing Medicine ; (36): 1851-1853,1856, 2014.
Artigo em Chinês | WPRIM | ID: wpr-572408

RESUMO

Objective To observe the clinical efficacy and safety of calcipotriol betamethasone ointment for the treatment of pso‐riasis vulgaris in the stable stage of patient .Methods This was a randomized ,parallel controlled clinical trials ,in which 90 patients with psoriasis vulgaris were randomly divided into experimental group and controlled group .All of them received 4 weeks of thera‐py .We compared the efficacy and safety 1 ,2 ,4 week after treatment by calcipotriol betamethasone ointment .Results About the clinical efficacy ,according to the decrease in percentage of psoriasis area and severity index (PASI) were:23 patients in the experi‐mental group were effective(efficacy rate is 76 .67% ) ,14 patients in control group Ⅰ was effective(efficacy rate is 46 .67% ) ,15 pa‐tients in control group Ⅱ was effective(efficacy rate is 50% ) .The differention between experimental group and the two control groups was significant(P< 0 .05 ,P< 0 .01) .After 1 ,2 ,4 weeks of therapy ,the decrease in percentage of PASI of experimental group is higher than that in the control groups .The scores of the observed erythema ,infiltration ,scale were decreased ,and the total scores of PASI are also decreased 4 weeks after therapy .The decrease score of experimental group is higher than that of control group Ⅰ(P<0 .01) and control group Ⅱ(P<0 .01) .The side effects of the experimental group are mild such as itching ,folliculi‐tis ,erythema ,and the laboratory examinations had no abnormal changes .Conclusion Calcipotriol betamethasone ointment was more effective to treat the stable stage psoriasis vulgaris patients compared with single use of halometasone or calcipotriol .It takes effect quickly ,and could be more feasible and safe .

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA